Business
Aurinia sells LUPKYNIS, an FDA-approved oral therapy for adult patients with active lupus nephritis, and is developing aritinercept for autoimmune diseases.
Aurinia revenue rose 20.4%, profit and free cash flow surged, and Kevin Tang bought $17.9M in the local window.
The read at a glance✓ Audited against SEC data
- Business mix — LUPKYNIS plus autoimmune pipelineNote
- Revenue — Revenue rose 20.4%OK
- Profit — Net income rose to $287.2MOK
- Cash — FCF rose to $135.4MOK
- Capital — Equity rose 54.0%OK
- Insiders — 6 buys / 1 sell; $17.9M boughtOK
- Accounting — Altman-Z grey; EQ safeNote
Where the revenue comes from
Fiscal 2025, as Aurinia Pharmaceuticals Inc. reports it. History and quarterly detail are in the app.
- Net product sales$271.3M
- License, collaboration and royalty revenue$11.7M
- Service Revenue$11.7M
Leadership changes
From Aurinia Pharmaceuticals Inc.'s own filings, the day they're filed.
- Ryan Cole · Chief Operating Officer · appointmenteff. 2026-03-23
- Michael Hearne · Chief Financial Officer · appointmenteff. 2026-03-23
- Kevin Tang · Chief Executive Officer · appointmenteff. 2026-03-23
Latest filings
- 8-K · Company announcement2026-08-19
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-06-04
- 8-K · Company announcement2026-05-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Aurinia Pharmaceuticals Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.